New genetic and protein biomarkers RAB31 and FN1 improve detection of recombinant hGH abuse
Background
Detecting human Growth Hormone (hGH) abuse in sports remains a significant challenge for anti-doping agencies. Since recombinant hGH (rhGH) became available in the 1980s, its illicit use has grown, necessitating more robust, sensitive, and reliable detection methods. Current tests often rely on measuring insulin-like growth factor 1 (IGF-1), which increases in response to hGH, but this marker has a limited detection window. Researchers are exploring alternative biomarkers that persist longer and are less affected by confounding factors. Previous work suggested that the FN1 (fibronectin 1) and RAB31 (member of RAS oncogene family) genes could be potential biomarkers for IGF-1 abuse, creating a rationale to investigate them directly in the context of rhGH administration.
Study Design
This study involved fourteen healthy male subjects who were administered recombinant human growth hormone (rhGH). The primary objective was to evaluate the response of specific genetic and proteomic markers to rhGH. Researchers analyzed blood samples to measure changes in FN1 gene expression, FN1 protein levels, RAB31 gene expression, and RAB31 protein levels. The study also included a preliminary assessment of potential confounding factors such as gender, age, acute sports activities, and the administration of GHRP-2 (pralmorelin), a growth hormone-releasing peptide, to test the specificity and robustness of these new potential biomarkers.
Results
The results demonstrated that rhGH administration significantly impacted the selected markers. Both the RAB31 gene and the FN1 gene showed measurable changes in expression following rhGH treatment. Additionally, the protein product of the FN1 gene, fibronectin 1, was also identified as a responsive biomarker. These findings suggest that a combination of genetic (RAB31, FN1) and proteomic (FN1 protein) measurements could serve as a powerful tool for detecting hGH abuse. Critically, the study highlights that these markers offer a superior detection capability compared to the current standard.
The selected markers,
RAB31andFN1, present high sensitivity and a larger detection window for rhGH detection than IGF-1 itself. Preliminary analysis indicated that these biomarkers are not significantly influenced by common confounding variables like gender, age, or acute exercise. Furthermore, the administration of GHRP-2, another performance-enhancing substance, did not appear to affect these markers, suggesting high specificity for direct rhGH administration.
Key Findings
- RAB31 gene expression is a potential biomarker for rhGH administration.
- FN1 gene expression is a potential biomarker for rhGH administration.
- FN1 protein level is a potential biomarker for rhGH administration.
- The new markers (RAB31, FN1) show higher sensitivity and a larger detection window than IGF-1.
- Preliminary data suggests gender, age, acute sports, and GHRP-2 are not relevant confounding factors.
Why It Matters
For athletes and regulatory bodies, this research provides a pathway to more effective and reliable anti-doping controls for hGH. The identification of RAB31 and FN1 as robust biomarkers could lead to new testing protocols that are harder to evade. These markers offer a longer detection window, meaning that athletes using rhGH could be identified for a longer period after their last dose, closing a critical loophole in current testing regimes. While promising, this is a preliminary study with a small sample size. Further validation in larger, more diverse cohorts is necessary before these biomarkers can be incorporated into official World Anti-Doping Agency (WADA) testing panels. The findings suggest that future anti-doping tests might involve a panel of genetic and protein markers rather than relying on a single indicator like IGF-1, making the system much more difficult to cheat.
